Cryopreserved Off-the-Shelf Allogeneic Adipose-Derived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure-A Safety Study.

نویسندگان

  • Jens Kastrup
  • Mandana Haack-Sørensen
  • Morten Juhl
  • Rebekka Harary Søndergaard
  • Bjarke Follin
  • Lisbeth Drozd Lund
  • Ellen Mønsted Johansen
  • Abbas Ali Qayyum
  • Anders Bruun Mathiasen
  • Erik Jørgensen
  • Steffen Helqvist
  • Jens Jørgen Elberg
  • Helle Bruunsgaard
  • Annette Ekblond
چکیده

The present first-in-human clinical trial evaluated the safety and feasibility of a newly developed and cryopreserved Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product from healthy donors for intramyocardial injection in ten patients with ischemic heart disease and ischemic heart failure (IHF). Batches of CSCC_ASC were isolated from three healthy donors by liposuction from abdominal adipose tissue. Adipose mesenchymal stromal cells were culture expanded in bioreactors without the use of animal constituents, cryopreserved, and stored in vials in nitrogen dry-storage containers until use. Direct injection of CSCC_ASC into the myocardium did not cause any complications or serious adverse events related to either treatment or cell administration in a 6-month follow-up period. Four out of ten heart failure patients developed donor-specific de novo human leukocyte antigen (HLA) class I antibodies, and two out of ten patients had donor-specific HLA antibodies already at baseline. There were no clinical symptoms or changes in inflammatory parameters in the follow-up period that indicated an ongoing immune response. There was a tendency toward improvement in cardiac function after CSCC_ASC treatment at 6-month follow-up: left ventricular end systolic volume decreased and left ventricular ejection fraction increased. In addition, exercise capacity increased. These changes were independent of the presence or absence of HLA antibodies. It is concluded that the newly developed cryopreserved product CSCC_ASC from healthy donors was a safe and feasible treatment. We observed a tendency toward efficacy in patients with IHF. These findings have to be confirmed in larger placebo controlled clinical trials. Stem Cells Translational Medicine 2017;6:1963-1971.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study

BACKGROUND Ischemic heart failure (IHF) has a poor prognosis in spite of optimal therapy. We have established a new allogeneic Cardiology Stem Cell Centre adipose-derived stromal cell (CSCC_ASC) product from healthy donors. It is produced without animal products, in closed bioreactor systems and cryopreserved as an off-the-shelf product ready to use. STUDY DESIGN A multicentre, double-blind, ...

متن کامل

Prevalence of Heart Failure in Patients With Ischemic Stroke: A Descriptive Study

Background: Cerebrovascular Accident (CVA) is the second cause of death and disability in the world. Heart failure can co-occur with CVA and increases the risk of death and disability in patients. Objectives: This study aimed to evaluate the prevalence of heart failure in patients with ischemic stroke. Materials & Methods: In this cross-sectional study, the information of patients with ischem...

متن کامل

An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.

RATIONALE Preclinical studies indicate that adult stem cells induce tissue repair by activating endogenous stem cells through the stromal cell-derived factor-1:chemokine receptor type 4 axis. JVS-100 is a DNA plasmid encoding human stromal cell-derived factor-1. OBJECTIVE We tested in a phase 1, open-label, dose-escalation study with 12 months of follow-up in subjects with ischemic cardiomyop...

متن کامل

Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy.

BACKGROUND AIMS Bone marrow (BM) mesenchymal stromal cells (MSC) represent a novel therapy for severe heart failure with extensive myocardial scarring, especially when performed concurrently with conventional revascularization. However, stem cells are difficult to transport in culture media without risk of contamination, infection and reduced viability. We tested the feasibility and safety of o...

متن کامل

Comparison of Vitamin D Serum Level in Patients with Cardiac Ischemic and Control Group at the Heart Hospital of Hamadan City

Introduction: During the recent years, vitamin D deficiency was determined as a risk factor for cardiovascular diseases. The purpose of this study was to evaluate the association of vitamin D with ischemic heart disease in the city of Hamadan. Methods: A case control-study was performed with 72 patients with ischemic heart disease, which had been confirmed by angiography in the case group. V...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Stem cells translational medicine

دوره 6 11  شماره 

صفحات  -

تاریخ انتشار 2017